GU CANCERS SYMPOSIUM 2024 ROUNDTABLE DISCUSSION: GETUG AFU 18
OR
Chair
Dr. Nazanin Fallah-Rad
Panelists
Dr. Sebastien Hotte
Dr. Maria Jiang
This program has been made possible through unrestricted support from EMD Serono & Ipsen
Studies/trials discussed:
- GETUG AFU 18 Study
- Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.
